|
USA-737904-ComputersNetworking 公司名录
|
公司新闻:
- The Evolving Landscape of Dry-eye Therapeutics
In May 2025, Aldeyra announced that their Phase III dry-eye chamber trial achieved its primary endpoint, with reproxalap significantly reducing patient-reported ocular discomfort compared to vehicle 1 This comes after the FDA issued a Complete Response Letter in April 2025, citing insufficient evidence of efficacy in treating DED symptoms from
- Improved Dry Eye Drugs for 2025 and Beyond
VEVYE (0 1% cyclosporine ophthalmic solution) by Novalique is a preservative-free, water-free drop that is designed to increase tear production in people with dry eye disease It contains the same active ingredient — an anti-inflammatory called cyclosporine — as Restasis and CEQUA
- Managing dry eye in 2025: Think bigger picture, multisystem
As we head into 2025, practitioners should consider the bigger picture when it comes to understanding the causes of dry eye and embrace a multifaceted approach to treatment to achieve better patient outcomes
- The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline
The first pharmaceutical to target an inflammatory pathway in order to treat dry eye is cyclosporine 0 05% (Restasis, Allergan; Irvine, CA, USA), which has become a mainstay of treatment for moderate to severe dry eye disease
- Emerging treatment strategies in dry eye disease: Potential of blood . . .
In this study, we review recent research on natural product treatments for DED, focusing on blood-derived therapies (e g , autologous serum, albumin serum, and allogeneic serum) and plant-based compounds such as omega-3 fatty acids (O3FA), omega-6 fatty acids (O6FA), antioxidants, polyphenols, and flavonoids
- Key Takeaways From ASCRS 2025: Understanding Recent Data for Treating . . .
A panelist discusses how dry eye disease involves tear film imbalance, leading to inflammation and ocular surface damage, emphasizing the importance of precise diagnosis and tailored treatment
- Novel Therapies in the Treatment of Dry Eye Disease: A Syste . . .
To the best of our knowledge, this study is the first meta-analysis to summarise the efficacy of autologous serum eye drops, stem cell therapy and the novel lipid-based treatment such as emulsion and liposome versus water-based artificial tear eye drops amongst patients with DED
- FDA approves new drops to treat dry eye disease - UCI Health
"Many of my patients continue to face frustrating challenges with dry eye management There is a clear need for additional treatment options " She also highlighted how the ophthalmic solution improves treatment "TRYPTYR is the first eye drop that stimulates corneal nerves to directly address tear deficiency, a known cause of dry eye disease "
- FDA Approves New Treatment for Dry Eye Disease - WebMD
May 30, 2025 -- The FDA has approved a new treatment for dry eye disease (DED) after studies showed it can help stimulate natural tear production as early as the first day of use The new drug
- CRSToday | Dry Eye Breakthroughs in the Making
IVW-1001 (iView Therapeutics) is a TRPM8 agonist designed to address the signs and symptoms of dry eye disease 1 Delivered via an ophthalmic eyelid wipe, IVW-1001 offers a novel, patient-friendly approach that could improve accessibility and compliance compared to traditional eye drop formulations
|
|